Company Overview and News
KUALA LUMPUR (March 29): The FBM KLCI reversed its earlier losses and rose firmly above the 1,700-point level at mid-morning.
The FBM KLCI, which opened 2.07 points weaker at 1,701.72, moved between 1,698.26 and 1,702.81 throughout the day. — Reuters picKUALA LUMPUR, March 28 ― The bellwether FTSE Bursa Malaysia KLCI (FBM KLCI) ended lower in lacklustre trading today, weighed down by heavyweights. The key index fell by 1.38 points to end at 1,702.41 against last Friday’s close of 1,703.79. The FBM KLCI, which opened 2.
KUALA LUMPUR (March 28): The FBM KLCI slipped below the crucial 1,700 point level at the mid-day break today, as investor sentiment at the local market turned weaker.
KUALA LUMPUR (March 28): The FBM KLCI remained in the negative territory at mid-morning today, weighed by select blue chips.
KUALA LUMPUR, March 25 — Share prices on Bursa Malaysia ended lower today, despite mostly bullish regional market, due to an overbought correction after the recent rally, dealers said.
KUALA LUMPUR (March 25): The FBM KLCI lost 0.49% at mid-morning today,as the local market took a pause in line with the weaker sentiment at most global markets.
KUALA LUMPUR, March 25 ― The bellwether FTSE Bursa Malaysia KLCI (FBM KLCI) opened lower on continuous profit taking in selected heavyweights, dealers said.
Among the gainers were Comintel Corp, surging 11.5 sen to 75.5 sen while Jaycorp added five sen to RM1.09 and CBIP four sen to RM2.32.
KUALA LUMPUR (March 25) : Comintel Corporation Bhd’s share prices surged as much 13 sen or 20% to 77 sen, and emerged as a top gainer in Bursa Malaysia this morning.
KUALA LUMPUR (Feb 24): The FBM KLCI extended its losses at the midday break today as regional markets stayed sluggish on declining crude oil prices. At 12.30pm, the FBM KLCI fell 9.55 points to 1,667.73. Losers thumped gainers by 554 to 164, while 274 counters traded unchanged. Volume was 706.26 million shares valued at RM594.16 million.
KUALA LUMPUR (Feb 24): The FBM KLCI remained in the negative zone at mid-morning today in line with the sluggish regional markets. At 10.10am, the FBM KLCI fell 4.12 points to 1,673.16. The top losers included Dutch Lady Milk Industries Bhd, Latitude Tree Holdings Bhd, British American Tobacco (M) Bhd, Sime Darby Bhd, Petronas Gas Bhd, Batu Kawan Bhd, Latitude Tree Holdings Bhd, Fiamma Holdings Bhd and Genting Bhd.
KUALA LUMPUR (Feb 4): Stocks on Bursa Malaysia may remain under pressure today with the FBM KLCI trending sideways cautiously ahead of the extended Chinese Lunar New Year holidays starting this weekend. The U.S. dollar tumbled on Wednesday after comments from a Federal Reserve official and a soft services sector report suggested a slowing pace of rate hikes, sparking a rally in oil prices that also boosted U.
It was a lacklustre day at Bursa Malaysia as sentiment at the local market stayed cautious, despite modest rise at regional bourses. At 12.30pm, the FBM…
KUALA LUMPUR (Jan 19): It was a lacklustre day at Bursa Malaysia as sentiment at the local market stayed cautious, despite modest rise at regional bourses. At 12.30pm, the FBM KLCI was up 2.89 points to 1,625.53. Losers overtook gainers by 366 to 361, while 337 counters traded unchanged. Volume was 1.08 billion shares, valued at RM662.21 million. The top gainers included British American Tobacco (M) Bhd, Lay Hong Bhd, Mercury Industries Bhd, Petron Malaysia Refining & Marketing Bhd, Scientex Bhd, Apollo Food Holdings Bhd, and SAM Engineering & Equipment Bhd.
The FBM KLCI stayed listless at mid-morning today in line with the subdued regional markets. At 10am, the FBM KLCI was up 1.13 points to 1,623.77.…
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...